Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

PeptiGrowth Inc. Launches Novel Synthetic KGF Alternative Peptide (FGFR2b Agonist)

stem cells. Product Overview Product name: KGF alternative peptide (FGFR2b agonist) Product code: PG-012 Product form: Lyophilized Storage conditions: -20°C or less Purity: ≥95% by HPLC Molecular weight: 6018.40 (Acetate) Size: 10 μg, 100 μg, 1 mg...

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company...

ELIQUENT Life Sciences Acquires Truliant Consulting, Expanding Pharmacovigilance Platform

knowledge, technology-driven approach, and operational scalability will expand ELIQUENT’s pharmacovigilance platform to offer clients a premier partner for regulatory success,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences....

Fast Company recognizes Bruin Biometrics as a top 10 innovative medical device maker

Bruin Biometrics LLC, a medical technology platform company that provides digital solutions for pressure injury prevention and management to health systems in the U.S. and U.K., announced it has been named by Fast Company as one of the World's 10...

Medline to launch a synthetic ligament augmentation implant.

foot and ankle orthopedic devices market insights, nearly 300,000 foot and ankle sports medicine procedures are performed in the U.S. each year, with ankle instability procedures representing approximately 44% of these surgical procedures. The...

Pint Pharma secures ANVISA approval for BESREMi® to treat Polycythemia Vera

According to Fernanda Bertasi, General Manager of Pint Pharma in Brazil, "ANVISA’s approval of BESREMi® represents a transformative milestone for patients with Polycythemia Vera in Brazil. This new therapeutic option brings real hope, offering...

Marking a new era of uncovering the potential of NAD+ with precision science, ChromaDex evolves into Niagen Bioscience

this strategic evolution underscores the Company’s true identity as the pioneer of NAD+ research and innovator behind transformative NAD-boosting healthy-aging solutions. At the forefront is Niagen Bioscience’s clinically proven, patented flagship...

Medit introduces SmartX, a new All-on-X solution for digital dentistry

dental clinics. About Medit: MEDIT is a global provider of 3D intraoral scanners and an all-in-one digital dentistry platform, based on its own patented state-of-the-art technology. The company also develops innovative software for digital...

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. For more information, please visit: https://www.actiniumpharma.com/

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

for the arts and sciences. The foundation was established in 2000 by Jan and Marica Vilcek, immigrants from the former Czechoslovakia. The foundation's mission was inspired by the couple's respective careers in biomedical science and art history....

Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial Reported by Blue Earth Therapeutics

Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio...

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

addition to advancing drug candidate safety and dosing, positive trial results will bolster confidence in the BioPYM platform as a groundbreaking therapeutics modality. No needle oral biologics with no cold-chain will transform the patient...

Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA, according to Currax Pharmaceuticals

settings. The latest analysis builds upon prior research, including the LIGHT trial, and complements the ongoing INFORMUS trial, a large-scale cardiovascular outcomes study, which now has enrolled more than 3,000 patients and is designed to meet...

Viking Therapeutics and CordenPharma Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables, and Oral Formulations

Agonist, across the full supply chain from drug substance to drug product for both its subcutaneous and oral peptide formulations. CordenPharma is committed to ensuring seamless development and commercialization of Viking Therapeutics' VK2735 drug...

Kenox Pharmaceuticals announces a strategic collaboration with Lactiga to advance immunotherapy targeting mucosal areas

designed to enhance mucosal immunity in individuals with compromised immune systems. The grant will advance Lactiga's platform sIgA technology while expanding Kenox's capabilities in inhaled and intranasal biologic delivery systems. "We are...

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

Head of Patient Evidence, UCB. "These five-year results highlight the robust potential of bimekizumab-bkzx in transforming patient outcomes by offering the possibility of lasting, complete skin clearance. Bimekizumab-bkzx is aiming to set a new...

MedaSystems secures additional seed financing to advance its AI-driven workflow platform, expanding access and supporting investigator-initiated studies

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva...

Newly-formed Archerfish Precision Diagnostics Pte Ltd ushers in a new era in advanced diagnostics

Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to form Archerfish Precision Diagnostics Private Limited (Archerfish). This strategic union brings together two leading laboratory...

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

of a dedicated sales force and market access teams and the commercial availability of IMKELDI, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers. "The launch of our sales force and market access teams is a...

"Latigo Biotherapeutics has been granted FDA Fast Track Designation for LTG-001, a potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain

for LTG-001. "We are pleased the FDA has granted Fast Track designation to LTG-001, recognizing its potential to transform the treatment landscape for acute pain by targeting pain at its source," said Nima Farzan, chief executive officer of Latigo....